These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 33289416)
1. Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. Claessen BE; Guedeney P; Gibson CM; Angiolillo DJ; Cao D; Lepor N; Mehran R J Am Heart Assoc; 2020 Dec; 9(24):e018897. PubMed ID: 33289416 [TBL] [Abstract][Full Text] [Related]
2. Treatment of dyslipidemia in acute coronary syndrome. Yadav S; Sawhney JPS Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S51-S57. PubMed ID: 38307382 [TBL] [Abstract][Full Text] [Related]
3. Current status of lipid management in acute coronary syndrome. Fujisue K; Tsujita K J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524 [TBL] [Abstract][Full Text] [Related]
4. Lipid management in ACS: Should we go lower faster? Gencer B; Mach F Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301 [TBL] [Abstract][Full Text] [Related]
5. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go? Qamar A; Libby P Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329 [TBL] [Abstract][Full Text] [Related]
6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
7. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705 [TBL] [Abstract][Full Text] [Related]
8. The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HIJ-PROPER Sub-Analysis. Arashi H; Yamaguchi J; Kawada-Watanabe E; Otsuki H; Sekiguchi H; Ogawa H; Hagiwara N J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):548-555. PubMed ID: 32567339 [TBL] [Abstract][Full Text] [Related]
9. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III. Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG; Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490 [TBL] [Abstract][Full Text] [Related]
10. Lipid Lowering Drugs in Acute Coronary Syndromes (ACS). Arnold N; Koenig W Curr Atheroscler Rep; 2023 Dec; 25(12):939-946. PubMed ID: 38015336 [TBL] [Abstract][Full Text] [Related]
11. Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. Nakamura M; Uno K; Hirayama A; Ako J; Nohara A; Arai H; Harada-Shiba M BMJ Open; 2017 Jul; 7(6):e014427. PubMed ID: 28674132 [TBL] [Abstract][Full Text] [Related]
14. Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome. García RV; García JEP; Navas WD; Salmerón DM; Mateos DB J Clin Lipidol; 2022; 16(5):635-642. PubMed ID: 35963739 [TBL] [Abstract][Full Text] [Related]
16. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. Sarak B; Savu A; Kaul P; McAlister FA; Welsh RC; Yan AT; Goodman SG Circ Cardiovasc Qual Outcomes; 2021 Apr; 14(4):e006646. PubMed ID: 33813856 [TBL] [Abstract][Full Text] [Related]
17. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. Grundy SM; Stone NJ JAMA Cardiol; 2019 Jun; 4(6):589-591. PubMed ID: 30994869 [No Abstract] [Full Text] [Related]
18. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. Sabatine MS; Giugliano RP JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310 [No Abstract] [Full Text] [Related]
19. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572 [TBL] [Abstract][Full Text] [Related]
20. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]